Nevirapine-d4

Nevirapine-d₄ is intended for use as an internal standard for the quantification of nevirapine by GC- or LC-MS. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It binds to HIV-1 reverse transcriptase and inhibits RNA plus-strand initiation (IC₅₀ = 0.45 μM). Nevirapine prevents seroconversion and viremia in a chimpanzee model of HIV-1 infection. Formulations containing nevirapine have been used in combination therapy for the treatment of HIV-1 infection.

Nevirapine-d4 (cyclopropyl-2,2,3,3-d4) (CAS# 1051418-95-1) is a useful isotopically labeled research compound. This can be prepared to use as non-nucleoside reverse transcriptase inhibitors.

HIV-1

[1] JAY A GROBLER. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.[J]. The Journal of Biological Chemistry, 2007, 282 11: 8005-8010. DOI: 10.1074/jbc.m608274200
[2] PETER M. GROB. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase[J]. Nature Medicine, 1997, 3 6: 665-670. DOI: 10.1038/nm0697-665